These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 22879989)

  • 1. FOXA1 promotes tumor progression in prostate cancer via the insulin-like growth factor binding protein 3 pathway.
    Imamura Y; Sakamoto S; Endo T; Utsumi T; Fuse M; Suyama T; Kawamura K; Imamoto T; Yano K; Uzawa K; Nihei N; Suzuki H; Mizokami A; Ueda T; Seki N; Tanzawa H; Ichikawa T
    PLoS One; 2012; 7(8):e42456. PubMed ID: 22879989
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FOXA1 promotes tumor progression in prostate cancer and represents a novel hallmark of castration-resistant prostate cancer.
    Gerhardt J; Montani M; Wild P; Beer M; Huber F; Hermanns T; Müntener M; Kristiansen G
    Am J Pathol; 2012 Feb; 180(2):848-61. PubMed ID: 22138582
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Androgen receptor-independent function of FoxA1 in prostate cancer metastasis.
    Jin HJ; Zhao JC; Ogden I; Bergan RC; Yu J
    Cancer Res; 2013 Jun; 73(12):3725-36. PubMed ID: 23539448
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FOXA1 modulates EAF2 regulation of AR transcriptional activity, cell proliferation, and migration in prostate cancer cells.
    Guo W; Keener AL; Jing Y; Cai L; Ai J; Zhang J; Fisher AL; Fu G; Wang Z
    Prostate; 2015 Jun; 75(9):976-87. PubMed ID: 25808853
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elevated levels of FOXA1 facilitate androgen receptor chromatin binding resulting in a CRPC-like phenotype.
    Robinson JL; Hickey TE; Warren AY; Vowler SL; Carroll T; Lamb AD; Papoutsoglou N; Neal DE; Tilley WD; Carroll JS
    Oncogene; 2014 Dec; 33(50):5666-74. PubMed ID: 24292680
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pioneer of prostate cancer: past, present and the future of FOXA1.
    Teng M; Zhou S; Cai C; Lupien M; He HH
    Protein Cell; 2021 Jan; 12(1):29-38. PubMed ID: 32946061
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Associations of CTCF and FOXA1 with androgen and IGF pathways in men with localized prostate cancer.
    Barker R; Biernacka K; Kingshott G; Sewell A; Gwiti P; Martin RM; Lane JA; McGeagh L; Koupparis A; Rowe E; Oxley J; Perks CM; Holly JMP
    Growth Horm IGF Res; 2023; 69-70():101533. PubMed ID: 37086646
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cooperativity and equilibrium with FOXA1 define the androgen receptor transcriptional program.
    Jin HJ; Zhao JC; Wu L; Kim J; Yu J
    Nat Commun; 2014 May; 5():3972. PubMed ID: 24875621
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FoxA1 specifies unique androgen and glucocorticoid receptor binding events in prostate cancer cells.
    Sahu B; Laakso M; Pihlajamaa P; Ovaska K; Sinielnikov I; Hautaniemi S; Jänne OA
    Cancer Res; 2013 Mar; 73(5):1570-80. PubMed ID: 23269278
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual role of FoxA1 in androgen receptor binding to chromatin, androgen signalling and prostate cancer.
    Sahu B; Laakso M; Ovaska K; Mirtti T; Lundin J; Rannikko A; Sankila A; Turunen JP; Lundin M; Konsti J; Vesterinen T; Nordling S; Kallioniemi O; Hautaniemi S; Jänne OA
    EMBO J; 2011 Sep; 30(19):3962-76. PubMed ID: 21915096
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FOXA1 promotes tumor cell proliferation through AR involving the Notch pathway in endometrial cancer.
    Qiu M; Bao W; Wang J; Yang T; He X; Liao Y; Wan X
    BMC Cancer; 2014 Feb; 14():78. PubMed ID: 24512546
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FOXA1: a transcription factor with parallel functions in development and cancer.
    Bernardo GM; Keri RA
    Biosci Rep; 2012 Apr; 32(2):113-30. PubMed ID: 22115363
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Altered chromatin recruitment by FOXA1 mutations promotes androgen independence and prostate cancer progression.
    Xu B; Song B; Lu X; Kim J; Hu M; Zhao JC; Yu J
    Cell Res; 2019 Sep; 29(9):773-775. PubMed ID: 31324884
    [No Abstract]   [Full Text] [Related]  

  • 14. Androgen receptor transcriptionally regulates semaphorin 3C in a GATA2-dependent manner.
    Tam KJ; Dalal K; Hsing M; Cheng CW; Khosravi S; Yenki P; Tse C; Peacock JW; Sharma A; Chiang YT; Wang Y; Cherkasov A; Rennie PS; Gleave ME; Ong CJ
    Oncotarget; 2017 Feb; 8(6):9617-9633. PubMed ID: 28038451
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Distinct structural classes of activating FOXA1 alterations in advanced prostate cancer.
    Parolia A; Cieslik M; Chu SC; Xiao L; Ouchi T; Zhang Y; Wang X; Vats P; Cao X; Pitchiaya S; Su F; Wang R; Feng FY; Wu YM; Lonigro RJ; Robinson DR; Chinnaiyan AM
    Nature; 2019 Jul; 571(7765):413-418. PubMed ID: 31243372
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FOXA1 knock-out via CRISPR/Cas9 altered Casp-9, Bax, CCND1, CDK4, and fibronectin expressions in LNCaP cells.
    Albayrak G; Konac E; Ugras Dikmen A; Bilen CY
    Exp Biol Med (Maywood); 2018 Aug; 243(12):990-994. PubMed ID: 30043639
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective targeting of PARP-2 inhibits androgen receptor signaling and prostate cancer growth through disruption of FOXA1 function.
    Gui B; Gui F; Takai T; Feng C; Bai X; Fazli L; Dong X; Liu S; Zhang X; Zhang W; Kibel AS; Jia L
    Proc Natl Acad Sci U S A; 2019 Jul; 116(29):14573-14582. PubMed ID: 31266892
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reprogramming of the FOXA1 cistrome in treatment-emergent neuroendocrine prostate cancer.
    Baca SC; Takeda DY; Seo JH; Hwang J; Ku SY; Arafeh R; Arnoff T; Agarwal S; Bell C; O'Connor E; Qiu X; Alaiwi SA; Corona RI; Fonseca MAS; Giambartolomei C; Cejas P; Lim K; He M; Sheahan A; Nassar A; Berchuck JE; Brown L; Nguyen HM; Coleman IM; Kaipainen A; De Sarkar N; Nelson PS; Morrissey C; Korthauer K; Pomerantz MM; Ellis L; Pasaniuc B; Lawrenson K; Kelly K; Zoubeidi A; Hahn WC; Beltran H; Long HW; Brown M; Corey E; Freedman ML
    Nat Commun; 2021 Mar; 12(1):1979. PubMed ID: 33785741
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nuclear mobility and activity of FOXA1 with androgen receptor are regulated by SUMOylation.
    Sutinen P; Rahkama V; Rytinki M; Palvimo JJ
    Mol Endocrinol; 2014 Oct; 28(10):1719-28. PubMed ID: 25127374
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nfib Regulates Transcriptional Networks That Control the Development of Prostatic Hyperplasia.
    Grabowska MM; Kelly SM; Reese AL; Cates JM; Case TC; Zhang J; DeGraff DJ; Strand DW; Miller NL; Clark PE; Hayward SW; Gronostajski RM; Anderson PD; Matusik RJ
    Endocrinology; 2016 Mar; 157(3):1094-109. PubMed ID: 26677878
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.